40.48
+0.11(+0.27%)
Currency In USD
| Previous Close | 40.37 |
| Open | 40.29 |
| Day High | 41.34 |
| Day Low | 39.63 |
| 52-Week High | 72.29 |
| 52-Week Low | 33.14 |
| Volume | 254,591 |
| Average Volume | 525,346 |
| Market Cap | 2.37B |
| PE | -16.66 |
| EPS | -2.43 |
| Moving Average 50 Days | 44.52 |
| Moving Average 200 Days | 47.94 |
| Change | 0.11 |
If you invested $1000 in Apogee Therapeutics, Inc. (APGE) since IPO date, it would be worth $1,906.74 as of February 05, 2025 at a share price of $40.48. Whereas If you bought $1000 worth of Apogee Therapeutics, Inc. (APGE) shares 1 year ago, it would be worth $1,124.44 as of February 05, 2025 at a share price of $40.48.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Apogee Therapeutics Announces First Patient Dosed in Part B of Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis
GlobeNewswire Inc.
Feb 03, 2025 12:00 PM GMT
Enrollment of Part A completed ahead of schedule and exceeded enrollment target with 123 patients enrolled Part A 16-week proof-of-concept data anticipated in mid-2025 SAN FRANCISCO and BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics,
Apogee Therapeutics to Participate at the Guggenheim SMID Cap Biotech Conference
GlobeNewswire Inc.
Jan 29, 2025 12:30 PM GMT
SAN FRANCISCO and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Wednesday, Februa
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of APG333, its Novel Half-Life Extended TSLP Antibody for the Treatment of Respiratory and Broader I&I Conditions
GlobeNewswire Inc.
Dec 10, 2024 12:00 PM GMT
Interim safety and pharmacokinetic data from Phase 1 healthy volunteers trial anticipated in 2H 2025 APG777 + APG333 can potentially address key drivers of respiratory diseases more broadly versus monotherapy Preclinical proof-of-concept achieved f